Total for the last 12 months
number of access : ?
number of downloads : ?
ID 116921
Author
Bando, Hiroshi Tokushima University|Japan Low Carbohydrate Diet Promotion Association KAKEN Search Researchers
Keywords
Imeglimin
Twymeeg
Trials of imeglimin for efficacy and safety 2 (TIMES 2)
Glucose-stimulated insulin secretion (GSIS)
Transient receptor potential melastatin 2 (TRPM2) channel
Content Type
Journal Article
Description
Imeglimin (Twymeeg) is novel oral hypoglycemic agent (OHA) developed in the glimin category. It has dual action mechanisms of reducing insulin resistance and increasing insulin secretion. Trials of imeglimin for efficacy and safety 1 (TIMES 1), TIMES 2 and TIMES 3 were performed with significant clinical efficacy. Among them, HbA1c decrease for 52 weeks showed single imeglimin -0.46%, combined therapy of dipeptidyl peptidase-4i (DPP-4i)-0.92%, Glucagon-like peptide-1 receptor agonists (GLP-1RA)-0.12% and insulin -0.63%. From physiological and pharmacological points of view, the mechanism may include the enhancement action of glucose-stimulated insulin secretion (GSIS). For GSIS progress, transient receptor potential melastatin 2 (TRPM2) channel is activated.
Journal Title
Diabetes Research : Open Journal
ISSN
23796375
Publisher
Openventio Publishers
Volume
8
Issue
1
Start Page
e1
End Page
e3
Published Date
2022-03-05
Rights
This is an open-access article distributed under Creative Commons Attribution 4.0 International License (CC BY 4.0) (https://creativecommons.org/licenses/by/4.0/), which allows to copy, redistribute, remix, transform, and reproduce in any medium or format, even commercially, provided the original work is properly cited.
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences